HIV Viral Load Patterns and Risk Factors Among Women in Prevention of Mother-To-Child Transmission Programs to Inform Differentiated Service Delivery

被引:0
作者
Jiang, Wenwen [1 ,11 ]
Ronen, Keshet [2 ]
Osborn, Lusi [3 ]
Drake, Alison L. [2 ]
Unger, Jennifer A. [2 ,4 ]
Matemo, Daniel [3 ]
Richardson, Barbra A. [5 ,6 ]
Kinuthia, John [3 ]
John-Stewart, Grace [7 ,8 ,9 ,10 ]
机构
[1] Univ Washington, Dept Epidemiol, Seattle, WA USA
[2] Univ Washington, Dept Global Hlth, Seattle, WA USA
[3] Kenyatta Natl Hosp, Dept Res & Programs, Nairobi, Kenya
[4] Brown Univ, Dept Obstet & Gynecol, Warren Alpert Med Sch, Providence, RI USA
[5] Univ Washington, Fred Hutchinson Canc Ctr, Dept Biostat, Div Vaccine & Infect Dis, Seattle, WA USA
[6] Univ Washington, Fred Hutchinson Canc Ctr, Dept Global Hlth, Div Vaccine & Infect Dis, Seattle, WA USA
[7] Univ Washington, Dept Global Hlth, Seattle, WA USA
[8] Univ Washington, Dept Med, Seattle, WA USA
[9] Univ Washington, Dept Pediat, Seattle, WA USA
[10] Univ Washington, Dept Epidemiol, Seattle, WA USA
[11] 3980 15th Ave NE, Seattle, WA 98105 USA
关键词
women; PMTCT; VL suppression; differentiated service delivery; Africa; longitudinal analysis; OPTION B PLUS; SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; POSTPARTUM WOMEN; PERINATAL DEPRESSION; FOLLOW-UP; CARE; SUPPRESSION; ADHERENCE; PREGNANCY;
D O I
10.1097/QAI.0000000000003352
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Differentiated service delivery (DSD) approaches decrease frequency of clinic visits for individuals who are stable on antiretroviral therapy. It is unclear how to optimize DSD models for postpartum women living with HIV (PWLH). We evaluated longitudinal HIV viral load (VL) and cofactors, and modelled DSD eligibility with virologic failure (VF) among PWLH in prevention of mother-to-child transmission programs. Methods: This analysis used programmatic data from participants in the Mobile WAChX trial (NCT02400671). Women were assessed for DSD eligibility using the World Health Organization criteria among general people living with HIV (receiving antiretroviral therapy for >= 6 months and having at least 1 suppressed VL [<1000 copies/mL] within the past 6 months). Longitudinal VL patterns were summarized using group-based trajectory modelling. VF was defined as having a subsequent VL >= 1000 copies/mL after being assessed as DSD-eligible. Predictors of VF were determined using log-binomial models among DSD-eligible PWLH. Results: Among 761 women with 3359 VL results (median 5 VL per woman), a 3-trajectory model optimally summarized longitudinal VL, with most (80.8%) women having sustained low probability of unsuppressed VL. Among women who met DSD criteria at 6 months postpartum, most (83.8%) maintained viral suppression until 24 months. Residence in Western Kenya, depression, reported interpersonal abuse, unintended pregnancy, nevirapine-based antiretroviral therapy, low-level viremia (VL 200-1000 copies/mL), and drug resistance were associated with VF among DSD-eligible PWLH. Conclusions: Most postpartum women maintained viral suppression from early postpartum to 24 months and may be suitable for DSD referral. Women with depression, drug resistance, and detectable VL need enhanced services.
引用
收藏
页码:246 / 254
页数:9
相关论文
共 68 条
  • [1] Abuogi LL, 2018, J VIRUS ERAD, V4, P33
  • [2] PMTCT care cascade and factors associated with attrition in the first four years after Option B plus implementation in Mozambique
    Ahoua, Laurence
    Tiendrebeogo, Thierry
    Arikawa, Shino
    Lahuerta, Maria
    Aly, Dario
    Journot, Valerie
    Abrams, Elaine J.
    Becquet, Renaud
    Dabis, Francois
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2020, 25 (02) : 222 - 235
  • [3] [Anonymous], 2018, Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya 2018 Edition
  • [4] [Anonymous], 2017, Transition to New Antiretroviral Drugs in HIV Programmes: Clinical and Programmatic Considerations
  • [5] [Anonymous], 2017, Differentiated Care: Operational Guide
  • [6] [Anonymous], 2012, Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants
  • [7] Retention in care and reasons for discontinuation of lifelong antiretroviral therapy in a cohort of Cameroonian pregnant and breastfeeding HIV-positive women initiating "Option B plus ' in the South West Region
    Atanga, Pascal N.
    Ndetan, Harrison T.
    Achidi, Eric A.
    Meriki, Henry D.
    Hoelscher, Michael
    Kroidl, Arne
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2017, 22 (02) : 161 - 170
  • [8] Barnabas RV, 2020, LANCET GLOB HEALTH, V8, pE1305, DOI 10.1016/S2214-109X(20)30313-2
  • [9] Viraemia before, during and after pregnancy in HIV-infected women on antiretroviral therapy in rural KwaZulu-Natal, South Africa, 2010-2015
    Chetty, Terusha
    Newell, Marie-Louise
    Thorne, Claire
    Coutsoudis, Anna
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2018, 23 (01) : 79 - 91
  • [10] Investigating the implementation of differentiated HIV services and implications for pregnant and postpartum women: A mixed methods multi-country study
    Chimukuche, Rujeko S.
    Wringe, Alison
    Songo, John
    Hassan, Farida
    Luwanda, Lameck
    Kalua, Thoko
    Moshabela, Mosa
    Renju, Jenny
    Seeley, Janet
    [J]. GLOBAL PUBLIC HEALTH, 2021, 16 (02) : 274 - 287